Latest bone metastasis Stories
Abstracts: 160, 182, 195, 202, 247, 253, 254 WHIPPANY, N.J., Feb. 23, 2015 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
Cardinal Health to build 64,000 square foot, state-of-the-art facility to manufacture radioactive therapeutic agent used to treat patients with bone metastases from castration-resistant prostate cancer WHIPPANY,
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif., Dec.
RSNA 2014: Radiological Society of North America Annual Meeting - McCormick Place, Chicago USA, November 30 - December 5th HAIFA, Israel, November 25, 2014 /PRNewswire/ --
This new genetic-based imaging technique is able to detect cancerous cells through expression of a gene called AEG-1. BETHESDA, MD (PRWEB) September 29, 2014
WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.
- An armed gangster.